LOBE.CN

L-130 passes 12 months ongoing stabilityVANCOUVER, British Columbia, December 05, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilize... Read More...

VANCOUVER, British Columbia, September 18, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Of... Read More...

First-in-Man trial for Lobe’s proprietary stabilized psilocin analogueAll subjects dosed with no significant adverse events to dateVANCOUVER, British Columbia, June 27, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare dis... Read More...

Phillips also named President of Altemia & Co., a Lobe Sciences CompanyVANCOUVER, British Columbia, June 07, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxter Phillips... Read More...

Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe’s Novel Sickle Cell Anemia Medical FoodVANCOUVER, British Columbia, May 17, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases t... Read More...

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Bran... Read More...

Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and commercial quantities of two new chemical entities, L-130 and L-131 under an exclusive arrangement Lobe Sciences Ltd. and QCL have entered ... Read More...

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of USD $250,... Read More...

Appointment of Philip J. Young, CEO, as Board ChairmanVancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it... Read More...

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible n... Read More...

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other init... Read More...

Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd... Read More...

Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with ... Read More...

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe"), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder ... Read More...

Vancouver, British Columbia--(Newsfile Corp. - February 14, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 11, 2022, it sold 8,000,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer ... Read More...

Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce that it has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB®. Lobe Sciences' common stock will commence trading on the OTCQB under th... Read More...

Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment ExperienceVancouver, British Columbia--(Newsfile Corp. - October 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Krysalis VX Innovations Inc. ("Krysalis")... Read More...

Appointment of Michael Petter to the Board brings another seasoned board member with strong industry, capital markets and strategic planning expertise.Vancouver, British Columbia--(Newsfile Corp. - January 8, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Mi... Read More...

Vancouver, British Columbia--(Newsfile Corp. - December 24, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company"), is pleased to announce that it has upsized its previously announced non-brokered private placement of units (the "Units") from $2,000,000 to up to $2,700,000 (the "Offering") and has completed a f... Read More...

Vancouver, British Columbia--(Newsfile Corp. - December 14, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it intends to raise up to Cdn$2,000,000 (the "Offering") through a non-brokered private placement of up to 20,000,000 units (the "Units") at a price of Cdn$0.10 per Unit... Read More...